IP Library › Granted Patent US 8,278,427
Granted Patent B2
US 8,278,427 · App. 10/460,467 · Granted Oct 2, 2012

Molecule for assigning genotype to phenotype and components thereof as well as method for constructing assigning molecule and method for utilizing assigning molecule

Assignee: KEIO University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,278,427
App. No.
10/460,467
Granted
Oct 2, 2012
Kind
B2
Abstract

An assigning molecule obtained by ligating a genotype molecule to a phenotype molecule by transpeptidation, wherein the genotype molecule is constructed by bonding (a) a spacer molecule comprising a donor region which can be bonded to a 3′-terminal end of nucleic acid, a PEG region bonded to the donor region and a peptide acceptor region which is bonded to the PEG region, to (b) a 3′ end of a nucleic acid comprising a 5′ untranslated region comprising a transcription promoter and a translation enhancer; an ORF region which comprises a polyA sequence and which is bonded to the 3′-terminal side of the 5′ untranslated region; and a 3′-terminal region that is bonded to the 3′-terminal side of the ORF region.

Claims (7)

1. A spacer molecule comprising a donor region which can be bonded to a 3′-terminal end of nucleic acid, a polyethylene glycol (PEG) region that is bonded to the donor region and comprises polyethylene glycol as a main component and a peptide acceptor region which is bonded to the PEG region and comprises a member selected from the group consisting of puromycin, 3′-N-aminoacylpuromycin aminonucleoside, and 3′-N-aminoacyladenosine aminonucleoside, wherein the donor region is deoxycytidylic acid or dideoxycytidylic acid, 5′-terminal end of the donor region being monophosphated, and wherein the PEG region is bonded to the donor region directly or via one or two residues of functionally modified deoxyribonucleotide or ribonucleotide.

2. A genotype molecule constructed by bonding a 3′-terminal end of a coding molecule to a 5′-terminal end of a donor region of a spacer molecule,

wherein said coding molecule is a nucleic acid comprising a 5′ untranslated region comprising a transcription promoter and a translation enhancer; an open reading frame (ORF) region which is bonded to the 3′-terminal side of the 5′ untranslated region and encodes a protein; and a 3′-terminal region that is bonded to the 3′-terminal side of the ORF region and comprises a polyA sequence, wherein the 3′-terminal region comprises a sequence which a restriction enzyme XhoI recognizes on the 5′-terminal end side of the polyA sequence; and wherein said spacer molecule comprises the donor region, a polyethylene glycol (PEG) region that is bonded to the donor region and comprises polyethylene glycol as a main component and a peptide acceptor region which is bonded to the PEG region and comprises a member selected from the group consisting of puromycin, 3′-N-aminoacylpuromycin aminonucleoside, and 3′-N-aminoacyladenosine aminonucleoside, wherein the donor region is deoxycytidylic acid or dideoxycytidylic acid and wherein the PEG region is bonded to the donor region directly or via one or two residues of functionally modified deoxyribonucleotide or ribonucleotide.

3. The genotype molecule according to claim 2 , wherein the transcription promoter is a promoter of SP6 RNA polymerase.

4. The genotype molecule according to claim 2 , which comprises an affinity tag sequence in a portion downstream from the ORF region.

5. The genotype molecule according to claim 4 , wherein the affinity tag sequence is a Flag-tag sequence, which is a tag for affinity separation and analysis based on an antigen-antibody reaction.

6. An assigning molecule constructed by ligating the genotype molecule as defined in claim 2 to a phenotype molecule which is a protein encoded by the ORF region in the genotype molecule, by transpeptidation.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S NAME AND ADDRESS PREVIOUSLY RECORDED ON REEL 033538 FRAME 0099. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Aug 21, 2014
From: KEIO UNIVERSITY
To: IDAC THERANOSTICS, INC.
Reel/Frame 033588/0269 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2014
From: KEIO UNIVERSITY
To: IDAC THERANOSTICS, INC. OF THE UNIVERSITY OF TOKYO ENTREPRENEUR PLAZA
Reel/Frame 033538/0099 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2003
From: YANAGAWA, HIROSHI; MIYAMOTO, ETSUKO; TAKASHIMA, HIDEAKI
To: KEIO UNIVERSITY
Reel/Frame 014185/0349 →
Priority Claims (1)
JP 2000-380562 · Dec 14, 2000 · national
Continuity (2)
Continuation PCTJP0110862 · Dec 11, 2001
Related Publication 20040018536A1 · Jan 29, 2004